Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

AstraZeneca launches ARIMIDEX Direct to help cancer patients

AstraZeneca today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.

17 Feb 2012

Increasing age associated with higher risk of death from breast cancer

Among postmenopausal women with hormone receptor-positive breast cancer, increasing age was associated with a higher risk of death from breast cancer, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Body's zinc control mechanisms may be key to aggressive breast cancer treatments

The body's control mechanisms for delivering zinc to cells could be key to improving treatment for some types of aggressive breast cancer.

6 Feb 2012

Researchers create vaccine that reduces tumors in mice

Researchers at Mayo Clinic in Arizona and the University of Georgia (UGA) have developed a vaccine that dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases - including those that are resistant to common treatments.

14 Dec 2011

Chemotherapy can cause cognitive problems in breast cancer survivors

A new analysis has found that breast cancer survivors may experience problems with certain mental abilities several years after treatment, regardless of whether they were treated with chemotherapy plus radiation or radiation only.

12 Dec 2011

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

8 Dec 2011

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.

8 Dec 2011

Notch inhibitor appears to treat breast cancer

In a novel therapeutic approach to treating breast cancer, Loyola University Medical Center researchers are reporting positive results from a clinical trial of a drug that targets tumor stem cells.

8 Dec 2011

Combination treatment extends lives of women with metastatic breast cancer

Changing the order in which two drugs are taken significantly extended the lives of women with metastatic breast cancer, a study has found.

8 Dec 2011

Male breast cancer patients report tamoxifen side effects

About half of male breast cancer patients who take the drug tamoxifen to prevent their disease from returning report side effects such as weight gain and sexual dysfunction, which prompts more than 20 percent of them to discontinue treatment, according to researchers at The University of Texas MD Anderson Cancer Center.

17 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

TWIST protein plays a major role in controlling estrogen resistance in breast cancer

In dozens of experiments in mice and in human cancer cells, a team of Johns Hopkins scientists has closely tied production of a cancer-causing protein called TWIST to the development of estrogen resistance in women with breast cancer.

8 Nov 2011

MicroRNA-101 can block autophagy in cancer cells

All cells in our body have a system that can handle cellular waste and release building blocks for recycling. The underlying mechanism is called autophagy and literally means "self-eating". Many cancer cells have increased the activity of this system and the increased release of building blocks equip the cancer cells with a growth advantage and can render them resistant towards treatment.

10 Oct 2011

Ibris to develop a quick and economical analysis of tissue from breast cancer biopsies

The National Institutes of Health (NIH) has awarded a Rutgers-affiliated company $207,000 to develop a quick and economical analysis of tissue from breast cancer biopsies. The technology is designed to predict how aggressive a common form of breast cancer is likely to be, helping physicians and patients plan effective therapies that minimize side effects.

7 Oct 2011

Drug combo for breast cancer in post-menopausal women shows promise

Combining two drugs in post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, a new study data showed.

26 Sep 2011

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome.

26 Sep 2011

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

26 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Study confirms tamoxifen is superior to fulvestrant in blocking estrogen

For the first time, researchers at Seattle Cancer Care Alliance have demonstrated the feasibility of using serial positron emission tomography (PET) scans, using a special estrogen-containing isotope, to confirm the relative effectiveness of estrogen-blocking and estrogen-depleting therapy in patients with metastatic breast cancer.

19 Aug 2011

Tamoxifen News and Research

Further Reading

AstraZeneca launches ARIMIDEX Direct to help cancer patients

Increasing age associated with higher risk of death from breast cancer

Body's zinc control mechanisms may be key to aggressive breast cancer treatments

Researchers create vaccine that reduces tumors in mice

Chemotherapy can cause cognitive problems in breast cancer survivors

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Notch inhibitor appears to treat breast cancer

Combination treatment extends lives of women with metastatic breast cancer

Male breast cancer patients report tamoxifen side effects

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

TWIST protein plays a major role in controlling estrogen resistance in breast cancer

MicroRNA-101 can block autophagy in cancer cells

Ibris to develop a quick and economical analysis of tissue from breast cancer biopsies

Drug combo for breast cancer in post-menopausal women shows promise

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Study confirms tamoxifen is superior to fulvestrant in blocking estrogen

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News